Key result
A 13-year-old boy developed fatal eosinophilic myocarditis and died approximately two months after initiating carbamazepine therapy for attention deficit-hyperactivity disorder.
Case Report (n=1)
This case report highlights a rare but fatal adverse event of eosinophilic myocarditis associated with carbamazepine therapy in a pediatric patient.
May warrant myocarditis vigilance with carbamazepine in children; hypothesis-generating and leaves causality open.
To the Editor: We describe a 13-year-old boy with attention deficit–hyperactivity disorder in whom fever, rash, conjunctivitis, hepatitis, myocarditis, and eosinophilia developed and who died about two months after the start of carbamazepine therapy. The cardiopulmonary resuscitation (CPR) of this patient was reported in an article on transvenous right ventricular pacing during CPR in children with acute cardiomyopathy.1 The child was an inpatient on a psychiatric unit. His carbamazepine treatment (100 mg twice a day) was initiated for aggressive and impulsive behavior after he did not respond to methylphenidate and clonidine. The carbamaz-epine dose was gradually increased to 800 mg . . .
No takes yet. Share an insight, caveat, or question.
Salzman et al. (1997) conducted a case report in Attention deficit-hyperactivity disorder (n=1). Carbamazepine was evaluated on Death due to eosinophilic myocarditis. A 13-year-old boy developed fatal eosinophilic myocarditis and died approximately two months after initiating carbamazepine therapy for attention deficit-hyperactivity disorder.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: